{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:19:08Z","timestamp":1783189148421,"version":"3.54.6"},"reference-count":17,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Outpatient cancer chemotherapy increasingly requires patients to manage oral anticancer agents at home, making adherence support and adverse event monitoring critical. Community pharmacists may contribute to treatment continuity through regular telephone follow-up (TFU), but evidence in the community pharmacy setting remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate the relationship between community pharmacy\u2013based TFU and treatment completion among patients receiving postoperative adjuvant chemotherapy for gastric or colorectal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective observational study of patients who received oral anticancer\u2013containing adjuvant chemotherapy at a community pharmacy in Japan between January 1, 2022, and December 31, 2024. Patients were classified into TFU and non-TFU groups according to whether a community pharmacist-led telephone follow-up was conducted after initial counseling. The primary endpoint was treatment completion based on the planned regimen duration. Patients who completed the planned treatment duration, including those requiring dose reductions or temporary postponements, were considered to have completed treatment. Adverse events were graded using CTCAE v5.0-JCOG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-three patients were included (TFU: n\u2009=\u200933; non-TFU: n\u2009=\u200930). The treatment completion was significantly higher in the TFU group than in the non-TFU group (58% vs. 23%, p\u2009=\u20090.006). Grade 1 adverse events were more frequently identified in the TFU group, whereas Grade 2 events were more common in the non-TFU group, suggesting earlier detection and intervention through TFU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Community pharmacist-led TFU may support treatment continuity and facilitate early detection of adverse events during adjuvant chemotherapy. These results highlight the role of community pharmacies in collaborative cancer care beyond hospital-based settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261464888","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:27:32Z","timestamp":1783016852000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of community pharmacy\u2013based telephone follow-up on treatment completion in cancer patients receiving adjuvant chemotherapy: A retrospective observational study"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9803-7773","authenticated-orcid":false,"given":"Norihiro","family":"Wada","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan"},{"name":"General Incorporated Association Senshu Medica, Kyowa Pharmacy, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Ishizaka","sequence":"additional","affiliation":[{"name":"Sakai City Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Hayashi","sequence":"additional","affiliation":[{"name":"General Incorporated Association Senshu Medica, Kyowa Pharmacy, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Omotani","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Myotoku","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.5649\/jjphcs.42.476"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.22-00160-4"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.5649\/jjphcs.51.203"},{"key":"e_1_3_3_5_2","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda MD: U.S. Department of Health and Human Services 2017."},{"key":"e_1_3_3_6_2","unstructured":"Japanese Society for Cancer of the Colon and Rectum. JSCCR Guidelines 2022 for the Treatment of Colorectal Cancer. Tokyo: Kanehara & Co. Ltd.; 2022. pp.31\u201333."},{"key":"e_1_3_3_7_2","unstructured":"Japanese Gastric Cancer Association. Gastric Cancer Treatment Guidelines 2021 (6th ed.). Tokyo: Kanehara & Co. Ltd.; 2021. p.38."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae241"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyx087"},{"key":"e_1_3_3_11_2","unstructured":"Ministry of Health Labour and Welfare. Report of the 18th Meeting on Cancer Care Provision System. Tokyo: Ministry of Health Labour and Welfare 2025. Available at: https:\/\/www.mhlw.go.jp\/content\/10901000\/001507662.pdf."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2480"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/1715163518802865"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.24-00016"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.2152\/jmi.71.141"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05875-2"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-018-0105-3"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211006348"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261464888","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261464888","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261464888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:57:04Z","timestamp":1783187824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261464888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":17,"alternative-id":["10.1177\/10781552261464888"],"URL":"https:\/\/doi.org\/10.1177\/10781552261464888","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"10781552261464888"}}